Focus: Exelixis is an oncology-focused biotech company centered on small-molecule tyrosine kinase inhibitors, with commercial operations headquartered in Alameda, CA. The company has built a revenue base primarily on CABOMETYX, a multi-indication cancer therapy at peak commercial maturity.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Hot — 61 jobs added in 30d
Net +42 (61 new, 19 removed). Aggressive expansion phase.
Exelixis offers solid oncology science and hiring momentum but carries structural concentration risk; best suited for professionals comfortable with mid-stage biotech volatility and oncology focus.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship revenue driver commanding $1.1B in Part D spending; multi-indication approved drug at commercial maturity with 8+ years to patent cliff.
Help build intelligence for Exelixis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Exelixis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
+2 more
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo